尽管收入增长了5.2%,但AngioDynamics的2026年第一季度亏损更大,这再次证实了2026年全年的预测. AngioDynamics posted a larger Q1 2026 loss despite 5.2% revenue growth, reaffirming full-year 2026 guidance.

AngioDynamics公司报告了其2026年问题的财务结果,披露了1.887亿美元的收入,即每年5.2%的增长,其驱动力是血管和肿瘤部门的增长。 AngioDynamics reported its Q1 2026 financial results, disclosing revenue of $188.7 million, a 5.2% increase year-over-year, driven by growth in its vascular and oncology segments. 该公司的净亏损为1 230万美元,即每股18美元,而去年同期亏损为1 090万美元,原因是研发和SG&A开支较高。 The company posted a net loss of $12.3 million, or $0.18 per share, compared to a loss of $10.9 million in the same period last year, citing higher R&D and SG&A expenses. 管理层重申了其2026年全年指导,预期收入在7.5亿至7.6亿美元之间,经调整的欧洲双边投资条约为1.5亿至1.55亿美元。 Management reaffirmed its full-year 2026 guidance, expecting revenue between $750 million and $760 million and adjusted EBITDA of $150 million to $155 million.